Literature DB >> 30066088

ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Jianbiao Zhou1,2, Yvonne Ng3, Wee-Joo Chng4,5,6.   

Abstract

ENL/MLLT1 is a distinctive member of the KMT2 family based on its structural homology. ENL is a histone acetylation reader and a critical component of the super elongation complex. ENL plays pivotal roles in the regulation of chromatin remodelling and gene expression of many important proto-oncogenes, such as Myc, Hox genes, via histone acetylation. Novel insights of the key role of the YEATS domain of ENL in the transcriptional control of leukemogenic gene expression has emerged from whole genome Crisp-cas9 studies in acute myeloid leukemia (AML). In this review, we have summarized what is currently known about the structure and function of the ENL molecule. We described the ENL's role in normal hematopoiesis, and leukemogenesis. We have also outlined the detailed molecular mechanisms underlying the regulation of target gene expression by ENL, as well as its major interacting partners and complexes involved. Finally, we discuss the emerging knowledge of different approaches for the validation of ENL as a therapeutic target and the development of small-molecule inhibitors disrupting the YEATS reader pocket of ENL protein, which holds great promise for the treatment of AML. This review will not only provide a fundamental understanding of the structure and function of ENL and update on the roles of ENL in AML, but also the development of new therapeutic strategies.

Entities:  

Keywords:  Acute myeloid leukemia (AML); ENL/MLLT1; Epigenetic therapy; Hematopoiesis; Histone acetylation; MLL

Mesh:

Substances:

Year:  2018        PMID: 30066088     DOI: 10.1007/s00018-018-2895-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  76 in total

1.  Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors:  Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

2.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors:  Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

Review 3.  A new world of Polycombs: unexpected partnerships and emerging functions.

Authors:  Yuri B Schwartz; Vincenzo Pirrotta
Journal:  Nat Rev Genet       Date:  2013-11-12       Impact factor: 53.242

4.  The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Authors:  Jianbiao Zhou; Chonglei Bi; Lip-Lee Cheong; Sylvia Mahara; Shaw-Cheng Liu; Kian-Ghee Tay; Tze-Loong Koh; Qiang Yu; Wee-Joo Chng
Journal:  Blood       Date:  2011-07-06       Impact factor: 22.113

5.  Leukemogenic MLL-ENL Fusions Induce Alternative Chromatin States to Drive a Functionally Dichotomous Group of Target Genes.

Authors:  Maria-Paz Garcia-Cuellar; Christian Büttner; Christoph Bartenhagen; Martin Dugas; Robert K Slany
Journal:  Cell Rep       Date:  2016-03-31       Impact factor: 9.423

6.  Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.

Authors:  Lesley F Drynan; Richard Pannell; Alan Forster; Nicole M M Chan; Florencia Cano; Angelika Daser; Terence H Rabbitts
Journal:  EMBO J       Date:  2005-08-11       Impact factor: 11.598

7.  Frat2 mediates the oncogenic activation of Rac by MLL fusions.

Authors:  Vanessa Walf-Vorderwülbecke; Jasper de Boer; Sarah J Horton; Renée van Amerongen; Natalie Proost; Anton Berns; Owen Williams
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

8.  Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.

Authors:  F Cano; L F Drynan; R Pannell; T H Rabbitts
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

Review 9.  Cytogenetic heterogeneity in t(11;19) acute leukemia: clinical, hematological and cytogenetic analyses of 48 patients--updated published cases and 16 new observations.

Authors:  J L Huret; A Brizard; R Slater; C Charrin; M F Bertheas; F Guilhot; K Hählen; W Kroes; E van Leeuwen; E V Schoot
Journal:  Leukemia       Date:  1993-02       Impact factor: 11.528

Review 10.  Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer.

Authors:  Ruichuan Chen; Jasper H N Yik; Qiao Jing Lew; Sheng-Hao Chao
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

View more
  5 in total

Review 1.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

Review 2.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 3.  Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.

Authors:  Yunlu Jia; Wee-Joo Chng; Jianbiao Zhou
Journal:  J Hematol Oncol       Date:  2019-07-16       Impact factor: 17.388

4.  Exome sequencing of glioblastoma-derived cancer stem cells reveals rare clinically relevant frameshift deletion in MLLT1 gene.

Authors:  Hany E Marei; Asmaa Althani; Nahla Afifi; Anwarul Hasan; Thomas Caceci; Armando Felsani; Giuseppe Tringali; Ingrid Cifola; Giacomo Pozzoli; Carlo Cenciarelli
Journal:  Cancer Cell Int       Date:  2022-01-07       Impact factor: 5.722

5.  New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.

Authors:  Giovanni Cugliari; Alessandra Allione; Alessia Russo; Chiara Catalano; Elisabetta Casalone; Simonetta Guarrera; Federica Grosso; Daniela Ferrante; Marika Sculco; Marta La Vecchia; Chiara Pirazzini; Roberta Libener; Dario Mirabelli; Corrado Magnani; Irma Dianzani; Giuseppe Matullo
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.